Lp-PLA2/PLA2G7 Proteins, Antibodies, cDNA Clones Research Reagents

PLA2G7 (Phospholipase A2 Group VII) is a protein coding gene located on human chromosome 6p12.3. PLA2G7 is also known as PAFAD, PAFAH, LP-PLA2 and LDL-PLA2. The human PLA2G7 gene encodes a 50077 Da protein containing 441 amino acids. The PLA2G7 protein is broadly expressed in appendix, lymph node and other tissues. Among its related pathways are Sweet Taste Signaling and Acyl chain remodelling of PE. PLA2G7 is related to phospholipid binding and calcium-independent phospholipase A2 activity. PAFAH2 is an important paralog of PLA2G7 gene. PLA2G7 is associated with some diseases, including Platelet-Activating Factor Acetylhydrolase Deficiency and Ige Responsiveness, Atopic.

Lp-PLA2/PLA2G7 Protein (2)

    Lp-PLA2/PLA2G7 Antibody (4)

      Lp-PLA2/PLA2G7 cDNA Clone (28)


      In cloning vector

      In lentiviral vector

      Lp-PLA2/PLA2G7 Lysate (2)

        Lp-PLA2/PLA2G7 Background

        Platelet-activating factor acetylhydrolase, also known as 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycero-phosphocholine esterase, Group-VIIA phospholipase A2, LDL-associated phospholipase A2, PAF 2-acylhydrolase, PLA2G7 and PAFAH, is a secreted protein that belongs to the AB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. PLA2G7 also represents an important, potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait that is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.

        Lp-PLA2/PLA2G7 References

        • Stafforini D.M., et al., 1996, J. Clin. Invest. 97:2784-2791.
        • Yoshida H., et al., 1998, Thromb. Haemost. 80:372-375.
        • Yamada Y., et al., 1998, Metabolism 47:177-181.
        • Kruse S., et al., 2000, Am. J. Hum. Genet. 66:1522-1530. 

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.